Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
U.S. stocks tick down as Apple drags tech sector lowerFlu season sees spike in drug productionUC Berkeley to host conference on geneByteDance's platform takes on U.S. eAutomotive future lies in integrated technology: ResearchChina's auto export ranks first globallyContainer shortage adds to export costsState energy firms turn to renewables abroadWorld should focus more on small businesses, young people: Jack MaChina reveals shortlist of 10 names for 1st Mars rover
2.0952s , 6499.7421875 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Culture Channel news portal